Head to head
McKesson vs Cencora
Side-by-side on the measures that matter, with a plain-English read. Full detail: MCK · COR
MCK
McKesson
1,069.43+0.68%
1-year price shape — +26% over the period
Quant Rating C · 72/100
vs
COR
Cencora
339.09-0.63%
1-year price shape — -6% over the period
Quant Rating D · 33/100
1-year performance, rebased to 100
McKesson edges it on the scoreable measures. McKesson has the highest Quant Rating (72); McKesson has done best over the past year (+26%); McKesson earns the most per share.
| MCK | COR | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Medical Distribution |
| Last price | 1,069.43 | 339.09 |
| Change today | +0.68% | -0.63% |
| 1-year return | +26.4% | -5.8% |
| Market cap | $123.47B | $64.71B |
| 52-week range | 722.11 – 1,121.50 | 243.32 – 374.62 |
| Valuation | ||
| P/E (TTM) | 27.48 | 18.89 |
| P/E percentile, own 5-yr range | 73rd | 28th |
| P/B | -31.23 | 17.58 |
| Dividend yield | 0.32% | 0.71% |
| Profitability & growth | ||
| EPS (TTM) | 38.55 | 17.95 |
| Net profit (TTM) | $4.45B | $3.43B |
| Revenue (TTM) | $418.79B | $337.40B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +7.6% | +5.5% |
| Gross margin | 3.7% | 4.1% |
| Operating margin | 1.7% | 1.4% |
| Net margin | 1.1% | 1.0% |
| Free cash flow (TTM) | $6.87B | $3.88B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 89.2% | 101.4% |
| Insider activity (12mo) | 21 buy / 27 sell | 31 buy / 17 sell |
| Short interest (% of float) | 1.7% | 1.7% |
| Analyst consensus | 90% buy / 10% hold (10) | 80% buy / 20% hold (10) |
| Analyst price target | $1,211 (+13%) | $386 (+14%) |
| StockVane view | ||
| StockVane Quant Rating | C (72) | D (33) |
| Company | ||
| Employees | 43,000 | 51,000 |
| Founded | 1833 | 1947 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.